CN101933932B - Application of 4-cyan-beta-D-glucoside in treating chronic neurogenic pain - Google Patents
Application of 4-cyan-beta-D-glucoside in treating chronic neurogenic pain Download PDFInfo
- Publication number
- CN101933932B CN101933932B CN2010101253485A CN201010125348A CN101933932B CN 101933932 B CN101933932 B CN 101933932B CN 2010101253485 A CN2010101253485 A CN 2010101253485A CN 201010125348 A CN201010125348 A CN 201010125348A CN 101933932 B CN101933932 B CN 101933932B
- Authority
- CN
- China
- Prior art keywords
- pain
- compound
- gabapentin
- chronic
- cyan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the application of a 4-cyan-beta-D-glucoside compound and pharmaceutically acceptable salts and esters and solvates thereof in preparing drugs for treating neurogenic pain, wherein the sugar part of glucoside is any pyranose or furanose, and the chemical name of the representative compound thereof is 4-cyan-beta-D-glucopyranoside, and the structural formula is shown in the specification. The inventor shows the definite anti-neurodynia therapeutic action of the compound on a classical sciatic nerve chronic constriction injury model (CCI) through single gastric lavage and continuous 7-day gastric lavage; in the dosage point specified by a test, the compound can obviously increase the mechanical stimulate feeling threshold; the anti-neurodynia efficiency is equivalent to equivalent Gabapentin of a contrast drug, whereas the time duration is higher than that of the Gabapentin. Prompted by a research result, the compound can be used for treating the chronic neurogenic pain.
Description
Technical field
The present invention relates to the pharmaceutical chemistry field, particularly, the present invention relates to 4-cyanic acid-β-D-glycoside compounds and officinal salt, ester and solvate thereof and be used to prepare the new purposes of treating chronic neuralgia.
Background technology
According to durante dolors length, clinical pain is categorized as two kinds of acute pain and chronic pains, these two kinds of pain have essential distinction on genesis mechanism.Acute pain is called nociceptive pain, the pain that promptly causes by tissue injury, and along with the reparation of tissue injury, pain stops naturally, between period of disease, can use analgesic (like narcotic analgesics and the agent of nonsteroidal antipyretic-antalgic) alleviating pain; Chronic pain is main with neuropathic pain then, and its pathogeny is complicated, and is difficult to radical cure, is the basis of pain medical science and the frontier of clinical research and medicament research and development.The external rise about 30 years has the research of 15-20 historical in China approximately.
One, neuropathic pain basic conception
Neuropathic pain is to cause the chronic pain due to nerve injury or the pathological changes by wound, inflammation or other diseases.Its exemplary comprises: the chronic pain that spine disorders compressing spinal cord or neural lumbago and backache, maincenter and the peripheral damage that causes cause, phantom limb pain behind the polyneuritis property pain of postherpetic neuralgia, diabetes, the apoplexy after pain syndrome, the amputation and intractable cancer pain etc.Neuropathic pain is considered to progressive nervous system disease, is the persistent state of the pain sensation, the adaptive change of neural plasticity and the biochemical reaction of secondary etc. with the difference of acute pain.
Neuropathic pain pathophysiology characteristics are pain sensation high responses, mainly show as: hyperpathia (hyperalgesia), to noxious stimulation increased response or sensitization; Allodynia (allodynia) produces the noxious stimulation reaction to non-noxious stimulation; Spontaneous pain (spontaneous pain) pain occurs under non-stimulated condition.
Since its complicated and diversified pathogeny with lack effective specific aim medicine (classical analgesic drug product such as opiates and nonsteroidal antipyretic analgesic are to such pain poor effect), neuropathic pain becomes on the clinical treatment comparatively stubborn problem.
Two, neuropathic pain pathogeny
The pain sensation high response of neuropathic pain shows as pain sensation threshold value and descends on animal experimental model, ectopic discharge etc. appears in the electroactive enhancing of Primary Sensory Neuron.Over nearly 5 years, the research of the mechanism of these phenomenons is obtained remarkable break-throughs.At present, the pathogenesis of proposition had both related to the neural approach of periphery property, also related to the neural approach of central.The neuralgia mechanism of main flow mainly contains following several kinds at present, in detail can be with reference to Long-Sun Ro, and Kuo-Hsuan Chang Neuropathic pain:Mechanisms andTreatments [J] .Chang Gung Med J28 (9): 597-604, that is:
1. the pain sensation is conducted neural quiet fiber activation and hyperpathia;
2. ion channel hypothesis (Na
+, Ca
2+): think in the tip aixs cylinder of injury nerve, to have several ion channels, these ion channels are specific pain transmitter.Gabapentin is considered to Ca
2+Ionic ion channel blocking agent;
3. neural factor hypothesis;
4. it is ultra quick to stimulating that nervus centralis enhanced sensitivity and plasticity change the nervus centralis that causes, and repairs unusual;
5. the maincenter conduction suppresses deficiency disease.
Three, neuropathic pain medicine
At present, the treatment neuropathic pain does not have specific medicine targetedly, and opiates and nonsteroidal antipyretic analgesic are to this type pain poor effect; Main medicine all belongs to old medicine and newly uses.These medicines are broadly divided into four types: Anti-epileptics, antidepressant, local anesthetic and other.
1. antuepileptic
Nineteen forty-two, Bergonignan reported first phenytoin Sodium can effectively be treated trigeminal neuralgia; Blom in 1962 reports carbamazepine first and also can effectively treat trigeminal neuralgia.But until eighties of last century eighties, relevant clinical research just system launches.Clinical research at present is verified: carbamazepine and gabapentin (gabapetin) can effectively suppress neuralgia.Research shows, carbamazepine block N a
+Passage suppresses Na
+Stride the film conduction, stop action potential to form, weaken the entad conduction of pessimal stimulation, suppress ectopic discharge; And suppress the rabbit trigeminal neuralgia that Kallidin I causes.U.S. FDA approved carbamazepine is used for prosopalgic treatment.Gabapentin analgesic mechanism research report shows that this medicine is to Na
+Do not have influence, maybe with blocking-up Ca
2+Passage is relevant because it can with N type Ca
2+The α of passage and δ
2Subunit combines.Other embody positive findings on animal model, but also need the medicine of further clinical experiment checking that phenobarbital, clonazepam, valproic acid, topiramate (Topiramate), helicide, Pregabalin and Tiagabine etc. are arranged.
2. antidepressant
Clinical research confirms that tricyclic antidepressants has analgesic activity to neuropathic pains such as postherpetic neuralgia, chronic low back pain, chronic tension headache, diabetic and non-diabetic polyneuritis pains.
But generally speaking, the untoward reaction of tricyclic antidepressants is more, and clinical use is restricted.
At present, external research to this compounds mainly concentrates on the analgesia research to the less second filial generation third generation antidepressant of untoward reaction.Type mainly contain the dual absorption inhibitor of 5-HT reuptake inhibitor, norepinephrine and 5-HT [like Paroxetine (Paroxetine), cedilanid (citaloprane), venlafaxine (venlafaxine) etc.).
3. local anesthetic
Local anesthetic is used maximum in this field be lignocaine.This chemical compound is typical C a
2+Channel blocker.1982, reports such as Boas can be alleviated maincenter and peripheral neuralgia with the lignocaine venous perfusion.Administering mode mainly concentrates on vein, subcutaneous perfusion and Taper Pipe perfusion at present.The end of the nineties in last century, drugs approved by FDA lidocaine patch, be mainly used in the neuropathic pain of local application treatment herpes zoster.
Four. the neuralgic correlational study of micromolecule phenol property glucoside for curing
The chemical compound 4-cyanic acid-β-D-glucosides that relates in this explanation is to be the analog of parent with micromolecule phenol property glucosides gastrodine and helicide.
Rhizoma Gastrodiae is the dry tuber of orchid Rhizoma Gastrodiae (Gastrodia elata); " the Chinese pharmacopoeia record, Rhizoma Gastrodiae is hidden sweet, slightly warm in nature, goes into Liver Channel; Have the relieving convulsion effect of suppressing the hyperactive liver to relieve the wind syndrome, cure mainly dizzy, the numb limbs and tense tendons of headache, infantile convulsion, epilepsy, hypertension and aural vertigo etc.
The main effective ingredient of Rhizoma Gastrodiae is micromolecule phenol property glucosides gastrodine (gastrodin; GAS); In recent years big quantity research has been carried out in the pharmacological action of Rhizoma Gastrodiae and composition thereof; In treatment is to have obtained new progress aspect the main multiple disease with the nervous system, finds that gastrodine has following effect: cerebral protection, improve cerebral circulation, convulsion, vertigo, anxiety, Fructus Alpiniae Oxyphyllae, slow down aging.Particularly, experiment shows that acegastrodine has analgesic activity; Compound tall gastrodia tuber preparation can comparatively fast improve the basic threshold of pain, the local skin temperature of reduction inflammation, the swelling degree that alleviates ankle joint, the reduction pain rank of pain model rat.Its mechanism maybe be with the transmission that reduces the pain material, reduce neural impulse import, activate that the analgesia system discharges analgesic matter and inhibition of pain gene expression is relevant into, and at present relevant with gastrodine analgesia research mainly concentrates on anti-acute pain aspect.
Bean curd is the Proteaceae plant for mountain Euphoria (Helicia Lour.) really, has the effect of convergence detoxifcation, blood circulation promoting and blood stasis dispelling, is used to treat enteritis, alimentary toxicosis, rheumatism disease such as swell and ache.By its clinical use of product Helicid sheet of processing for many years.
(helicid, chemical constitution HEL) is similar to Gastrodine to main effective ingredient helicide in the bean curd fruit.
Clinical, pharmacological research shows that helicide is similar with Gastrodine to central nervous system's effect, but its calmness, analgesic effect are strong than Gastrodine, and the therapeutical effect produce effects of the headache that neurosis is caused, giddy, sleep disorder is fast.Have and discover that helicide has the effect of antagonism inflammatory pain and neuropathic pain.Its analgesia characteristics are that onset is slow, the analgesic dose is little, long action time, no obvious toxic-side effects under the analgesic dose.The document Liu Gui that sees reference is gorgeous, Wang Gangli, Ma Shuancheng, the mountain Euphoria active components in medicinal plant research overview [J] of Lin Ruichao. Chinese medicine, 2004,35 (5): 593-595.
Give Mus tail heat injury sexual stimulus with the resistance wire heat radiator, observe the influence of helicide, helicide (2%, 1.5 * 10 rat whipping pain response time threshold value
-2ML/g, ip.), threshold value obviously raises and more than the lasting 30min; Bestow acusector and helicide (2%, 715 * 10 simultaneously
-3ML/g, ip.) after, threshold value significantly raises and can continue until and stops 50min behind the pin, shows that helicide has analgesia and prolongs the effect of needle anaesthesia effect.Document Chen Z X sees reference; Lou ZC.A preliminary study of theanalgesic action of D-fornyl-phenyl-β-D allosupranoside [J] .Acad J First Med Coll.PLA (No.1 Military Medical Univ.'s journal); 1985,5 (3): 186-187.Oral tablet by helicide is processed proves that with " writhing method " and " hot plate method " these article have analgesic activity.Document sees reference: Sha J M, Mao H K.Helicid [J] .Chin Pharm Bull (pharmacy circular), 1987,22 (1): 27.
Zhao Nan has the effect that resists neuropathic pain in reported first helicide in 2005.This research is thought; (6.25～50mg/kg) can improve CCI injury in rats batter palm pressure pain threshold value by dose dependent to oral helicide; The onset in 2 hours of its analgesic activity; 3 hours, 4 hours analgesic effect increases gradually after the administration, administration after 24 hours analgesic effect descend to some extent, 48 hours are still effective.Document sees reference: Zhao Nan, Yang Hongju, Wang Yanhua etc. and the anti-neuropathic pain pharmacodynamics of helicide is estimated [J]. Chinese pharmacology communication, 2005,22:38～39.
Gastrodine and helicide are safe and effective, take continuously and do not find to poison or other side reaction, and drug effect is constant.Its shortcoming be onset slowly, action intensity is weak, dosage is big, bioavailability is lower etc.This two chemical compound has similar chemical constitution, all is β-type pyranoside, and difference is the different of functional group and glycosyl.
The structural modification of medicine is to improve curative effect, and enhancing absorbs, and reduces the effective ways of side effect.Document sees reference: WeiguoShi; He Liu, Yanping Zhang, Bohua Zhong; Honiu Yang.Design; Synthesis, and preliminaryEvaluation of gabapentin-pregabalin mutual prodrugs in relieving neuropathic pain [J] .Arch.Pharm.Chem.Life Sci.2005,338:358-364.。The present invention is reference with gastrodine and helicide, its chemical constitution is modified, and the neuropharmacology activity of such analog is screened, and has obtained the potential new compound XH002 of treatment pathological pain.
Five. common chronic neuralgia drug evaluation model
[7,8]
Document sees reference: Yang Hongju; Jiang Zhongwei; Luo Zhipu. the diversity ratio of neuropathic pain animal model is [J]. Chinese clinical rehabilitation; 2003,7 (31): 4272-4273 and Yang Rong. with the helicide is neuropharmacology screening active ingredients research [M] .2007 of the micromolecule monoglycosides chemical compound of representative, Yunnan University's chemical science and engineering college.
Hot plate, whipping, turn round the classical animal model that body is the screening acute pain analgesic used always, but be not suitable for being used for screening the neuralgia medicine.The foundation of NP animal model in recent years development is played great impetus to mechanism of action and the drug research of NP.These have simulated clinically to a certain extent, and several kinds of conventional animal models of NP patient's symptom comprise: 1. peripheral nervous transection model (the sciatic nerve axotomy model); 2. the chronic compressing damage model of sciatic nerve (the chronic constriction injury model, CCI), this method elder generation EXPOSED RATS sciatic nerve-trunk; Reuse chromic catgut untwisting is pricked 4 rings; Animal postoperative 5～7d occurs machinery, and hot and cold IR is strengthened, and 10～14d peaks; And sustainable one or two months, be the neuropathic pain animal model of using always; 3. sciatic nerve partly cut off model (the partial sciatic nerve ligationmodel, PSL); 4. spinal nerves ligation model (the L5/L6 spinal nerve ligation model, SNL); 5. damage model (the spared nerve injury model) is selected by sciatic nerve branch.In addition, also have excitatory amino acid damage, dynorphin model, micro-duct injury model and diabetic neuralgia model or the like.
In recent years, the CCI model that people such as people's extensive use Bennette set up is simulated the rational pain of chronic neuropathic in clinical, inquires into hyperalgesic mechanism and exploitation NP curative.The CCI model document that sees reference: Bennett GJ, Xie YK.Aperipheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man [J] .Pain 1988; 33:87-107.The characteristics of this model are neural with the slight ligation of chromic suture, and the thick myelin fiber that has is optionally damaged, but still keep most of C fibrid that transmits pain.The animal of accepting this operation produces hyperpathia and allodynia to machinery and thermostimulation generation subsequently; The mensuration of subordinate act is found; The peripheral nerve injury of this state and human body, the symptom of the neuropathic chronic pain of bringing out like oncothlipsis, heavy metal ion poisoning, anoxia or Developmental and Metabolic Disorder etc. is very similar with the behavior performance.Simultaneously, CCI pain rat model is the ingenious combination of neuropathic pain and inflammatory pain just, and the inflammatory mediator molecule that the ectopic discharge that axonal injury causes because pain is and ligature place inflammatory cell discharge stimulates and produces due to the raising of dystopy sensitivity.
This experiment promptly utilizes CCI pain rat model that representation compound XH002 is carried out the active screening of anti-chronic neuralgia, measures mechanical allodynia and hyperpathia as evaluation index with Von-Frey Filament.
Summary of the invention
It is the 4-cyanic acid-β-D-glucoside compound of part that the present invention proposes with the following formula: compound, or its officinal salt, ester or solvate, is used for treating the purposes of the medicine of neuropathic pain in preparation:
Part is a chemical compound: the 4-cyanophenol
Wherein, glycosyl part is any pyranose or furanose.
Representative compound is 4-cyanic acid-β-D-pyranglucoside, is numbered XH002.The analog of this series of compounds helicide and gastrodine, structural formula is following:
This chemical compound is white to a cream-coloured granular crystal, no special odor.Dissolving fully in water, methanol, ethanol, the dimethyl sulfoxine, most of dissolving in the methanol.Insoluble in the ether.
At present, do not find the report that this chemical compound is applied to neuralgia research.The inventor is through discovering, the said chemical compound of patent can be used to treat neuropathic pain.
The objective of the invention is to propose a kind of new purposes of above-claimed cpd; Promptly the invention provides the purposes that chemical compound is used to prepare the medicine of treating the neuropathic pain disease.
Invent the neuropathic pain of the complicacy that described neuropathic pain refers to cause because of peripheral nerve injury, compressing, neurotoxicity, infection, immunity, metabolic disease, tumor, vitamin deficiency or other reasons.
Chronic pain and intractable cancer pain that the spinal cord that the neuropathic pain that the present invention is directed to mainly is the phantom limb pain, central pain, phantom pain, stump pain, sympathetic nerve dependency pain after pain syndrome behind postherpetic neuralgia, trigeminal neuralgia, sciatica, the damaging neuropathic pain of metabolism, the apoplexy, the amputation, complicated local pain syndrome, spine disorders causes or nerve root compression pain, maincenter and periphery wound cause.
Wherein said sciatica refers in particular to sciatic nerve chronic constriction neuropathic pain; The damaging pain of said metabolism is refered in particular to diabetes type neuralgia.
The anti-neuropathic pain medicine of officinal salt, ester or the solvate of 4-cyanic acid-β that this invention relates to-D-glucosides or its analog and quick-acting (particularly gabapentin) can form composition of medicine, adds the optional pharmaceutically acceptable excipient of protection, carrier or adjuvant simultaneously with patent medicine and listing.
Invention is on the chronic compressing damage model of the sciatic nerve of classics (CCI), and single filling stomach and continuous 7 days filling stomaches give this chemical compound and all shown clear and definite neuralgia therapeutical effect.On this model, single-dose and continuous 7 days administration effective doses are 45mg/kgBW.On this dose point, the compounds X H002 mechanical irritation threshold of pain that can significantly raise, neuralgia usefulness is suitable basically with equivalent control drug gabapentin, and duration of efficacy is superior to gabapentin.
Description of drawings:
Accompanying drawing 1 is the different rat pressure in the sky threshold of pain, a CCI operation back change curve;
Accompanying drawing 2 is that CCI rat single is irritated stomach gabapentin, gastrodine, 4-cyanic acid-β-24 hours Time-activity-curves of D-pyranglucoside
Accompanying drawing 3 is that the CCI rat was irritated stomach gabapentin, gastrodine, 4-cyanic acid-β-D-pyranglucoside Time-activity-curve in seven days
The specific embodiment
Concrete pharmacological evaluation is following:
One, receives the reagent thing
Title: 4-cyanic acid-β-D-pyranglucoside (XH002)
Character: white to cream-coloured granular crystal
The source: Yunnan University's natural resources pharmaceutical chemistry laboratory biochemical pharmacology group is synthetic voluntarily;
Medicine preparation, administration volume, and route of administration: face to grind and be suspended to desired concn with the pure water solution that before adds 0.2% sodium carboxymethyl cellulose.Rat gastric infusion every day once, the administration volume is 45mg/Kg, 10mL/Kg.
Two, control drug
1. gabapentin, available from Sigma company, CAS Number:60142-96-3.
2. gastrodine, Kunming pharmaceutical factory provides.Lot number: 200610036.
The pure water solution grinding of facing with preceding 0.2% sodium carboxymethyl cellulose is suspended to 45mg/mL concentration.
Three, laboratory animal
The Sprague-Dawley rat: regular grade, male, body weight 180～220g during operation provides credit number by animal section of unming Medical College: SCXK (Yunnan) 2008～2011.
Four, data statistics is handled
Data result is represented with mean+SD (
); Adopt SPSS 13.0 statistical packages as statistical tool; Not not on the same group and relatively adopt a plurality of independent sample Kruskal-Wallis H check in the non parametric tests between the normal group, with P＜0.05 for statistical significance is arranged.
Five, experimental technique
1. the foundation of rat CCI model
Reference material is seen: Bennett GJ, Xie YK.A peripheral mononeuropathy in rat that produces disordersof pain sensation like those seen in man [J] .Pain 1988; 33:87-107.
Rat is got the ventricumbent position fixing limbs in the rat operating-table with 40mg/kg BW pentobarbital sodium ip administration anesthesia; The right hind thigh stage casing outside is with bending operating scissors QUMAO, 70% alcohol disinfecting skin; Cut cortex, the mosquito forceps passivity is separated leg muscle, exposes sciatic nerve-trunk; Play the place for about 3 millimeters at the front end of sciatic nerve bifurcated, sciatic nerve is separated with surrounding tissue with aseptic glass hook; Prick 4 rings with No. 4 aseptic chromic sutures (diameter 0.15mm) untwisting on sciatic nerve-trunk, each ring spacing is about 1mm, ligation intensity to cause the slight vibration of Calf muscle but link can on nerve, move and be advisable; With silk thread layer-by-layer suture muscular tissue and skin, behind the operation ventrolateral compartment injection 40mg/Kg penicillin sodium normal saline solution, place the cage that is covered with cork dust.The sham operated rats rat only exposes sciatic nerve, and remaining processing is identical with model group.
2. the rat mechanicalness pain sensation is measured unusually
Reference material is seen: Tabo E; Jinks SL; Eisele Jr JH; Carstens E.Behavioral manifestations ofneuropathic pain and mechanical allodynia, and changes in spinal dorsal horn neurons, followingL4-L6 dorsal root constriction in rats [J] .Pain 1999; 80:503-20.
The threshold of reaction of mechanical stimulus is with Touch Test sense of touch test pack (VON-FREY FILAMENT), 58011 types, and North CoastMedical Inc. product is measured.(table 1 is seen in threshold of pain rank and the contrast of ballast gram number)
The animal of experimental selection postoperative 14～31d is measured the pressure of foundation threshold of pain before administration, eliminate the basic threshold of pain greater than 5.88 or less than 1.65 animal, all the other animal random packet; Single perhaps gave specific medication in continuous 7 days.
The mechanicalness pain sensation of METHOD FOR CONTINUOUS DETERMINATION animal is unusual after last administration; Survey before the pain earlier experimental rat is placed in several metal cylinder moulds tranquillization 30min at least respectively; Make it to be familiar with environment and be in quiescent condition, survey the pain process and under the glitch-free environment of peace and quiet, carry out.
The unusual assay method of the mechanicalness pain sensation: rat is placed metal cage; Adopt a series of survey pain pins that can produce different pressures vertically to stimulate its operation parapodum foot heart position from small to large successively from bottom to top; Make its mao hettocyrtosis and keep 5s, each stimulus intervals 5s.Find 10 times this cause that 4～6 rats lift the cellosilk of foot reaction in stimulating, write down this filametntary numerical value and be the rats withdraw foot threshold of reaction (paw withdrawal threshold, PWT).Maximum pain threshold is set at 6.65.Regulation is worked as 6.65 value cellosilks stimulates the sufficient heart to surpass 12s, and all not reacting fully under rat stimulates for 8 times is 6.95.
Table 1:TouchTest sense of touch test pack pressure and threshold of pain numerical value synopsis
Six, experimental result
1.CCI the different number of days rat pressure threshold of pain, operation back changes
Measure blank control group, sham operated rats, CCI organizes in back 3 days to 31 days pressure threshold of pains of operation.Changing contrast according to the sham operated rats pain learns; CCI organizes rat, and after operation 8 days, surgical injury can be ignored; Its pain is regarded as the allodynia that neural ligation causes, and shows as the operation lateral pressure threshold of pain and is starkly lower than non-operation side and blank control group and sham operated rats.
As index, the ultra quick phenomenon of pain presents little radian U type and changes, and presents minor swing in back 11 days to 28 days in operation, and after 28 days, raises gradually, points out neural ligation to absorb gradually with chromic catgut with the pressure threshold of pain, and the compressing phenomenon alleviates gradually.The result sees accompanying drawing 1.
2. the single gastric infusion is to the influence of the CCI rat pressure threshold of pain
After the single gastric infusion blank solvent, gastrodine, 4-cyanic acid-β-D-pyranglucoside, gabapentin 45mg/Kg1 hour, measure Time-activity-curve in the medicine 23 hours.Curve is seen accompanying drawing 2.
Results suggest, the allodynia that CCI causes is all alleviated in each administration group administration 1 hour to 23 hours in various degree.Explanation is on this model, and it is active that gastrodine, 4-cyanic acid-β-D-pyranglucoside, gabapentin all can embody anti-chronic neuropathic pains.Wherein, 4-cyanic acid-β-D-pyranglucoside, gabapentin 45mg/Kg can significantly improve mechanical hyperalgesia pressure pain threshold value, and analgesia time continues 23 hours; Onset time, persistent period and effect are superior to gastrodine.Cyanic acid-β-the D-pyranglucoside is effective and long lasting potential anti-chronic neuralgia medicine to prompting 4-.
Back 7 days successive administration timeliness situation 3.CCI perform the operation
Behind continuous 7 days gastric infusion blank solvent, gastrodine, 4-cyanic acid-β-D-pyranglucoside, the gabapentin 45mg/Kg, from last administration 1 hour, Time-activity-curve in the METHOD FOR CONTINUOUS DETERMINATION 140 hours.Curve is seen accompanying drawing 3.
Results suggest, each administration group administration is all alleviated the allodynia that CCI causes after 1 hour to 96 hours in various degree.Wherein, gabapentin administration analgesia duration is 1 hour to 43 hours; 1～32 hour gastrodine persistent period; 4-cyanic acid-β-D-pyranglucoside administration 45mg/Kg can significantly improve mechanical hyperalgesia pressure pain threshold value, and analgesia time continues 96 hours (with the sham operated rats contrast), and drug effect and persistent period are superior to gabapentin; Prompting gives the anti-chronic neuropathic pains activity that 4-cyanic acid-β-D-pyranglucoside can embody the long term for a long time continuously.
Seven, conclusion
1.4-cyanic acid-β-D-pyranglucoside all can embody anti-chronic neural source pain in 80 hours after single-dose 23 hours and administration in continuous 7 days active;
2.4-the drug effect of cyanic acid-β-D-pyranglucoside, persistent period all are superior to contrasting medicine gabapentin and analog gastrodine, have embodied good anti-neuropathic pain effect.
Explanation thus, this chemical compound can be prepared into the medicine of the various dosage forms that are used for and so on the neuropathic pain disease.Such compound effects time is long, and toxicity is low, is fit to take for a long time, and good new drug development prospect is arranged.
Claims (3)
1. the following 4-cyanic acid-β-D-pyranglucoside of structural formula or its officinal salt are used for treating the purposes of the medicine of chronic neuropathic pains in preparation:
2. purposes as claimed in claim 1 is characterized in that: said neuropathic pain is a sciatica.
3. purposes as claimed in claim 2 is characterized in that: said sciatica is a sciatic nerve chronic constriction neuropathic pain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101253485A CN101933932B (en) | 2010-03-16 | 2010-03-16 | Application of 4-cyan-beta-D-glucoside in treating chronic neurogenic pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101253485A CN101933932B (en) | 2010-03-16 | 2010-03-16 | Application of 4-cyan-beta-D-glucoside in treating chronic neurogenic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101933932A CN101933932A (en) | 2011-01-05 |
| CN101933932B true CN101933932B (en) | 2012-05-23 |
Family
ID=43387653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101253485A Expired - Fee Related CN101933932B (en) | 2010-03-16 | 2010-03-16 | Application of 4-cyan-beta-D-glucoside in treating chronic neurogenic pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101933932B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074582A (en) * | 2016-07-12 | 2016-11-09 | 昆明学院 | 4 cyano group β D glucoside compounds purposes in the medicine preparing treatment anxiety neurosis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1428345A (en) * | 2002-11-22 | 2003-07-09 | 云大科技股份有限公司 | Chemical synthesis process for preparing gastrodin and its analogous henolic glycoside formula (I) |
| CN1634089A (en) * | 2003-12-29 | 2005-07-06 | 昆明贝克诺顿制药有限公司 | Application of P-benzaladehyde-O-beta-D-allopyranose for the treatment of neurogenic pain |
-
2010
- 2010-03-16 CN CN2010101253485A patent/CN101933932B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1428345A (en) * | 2002-11-22 | 2003-07-09 | 云大科技股份有限公司 | Chemical synthesis process for preparing gastrodin and its analogous henolic glycoside formula (I) |
| CN1634089A (en) * | 2003-12-29 | 2005-07-06 | 昆明贝克诺顿制药有限公司 | Application of P-benzaladehyde-O-beta-D-allopyranose for the treatment of neurogenic pain |
Non-Patent Citations (1)
| Title |
|---|
| 戴晓畅等.天麻素及其类似酚性糖甙的化学合成工艺研究.《云南民族大学学报(自然科学版)》.2004,第13卷(第2期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101933932A (en) | 2011-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102895460B (en) | Traditional Chinese medicine composition for fracture and soft tissue injury | |
| CN100415240C (en) | Use of parapheny for maldehyde-O-beta-D-allose pyranoside for treating neurogenic pain | |
| CN101829132B (en) | Application of 7-O-beta-D-acetylation sugar-coumarin compounds in treating chronic neuropathic pains | |
| CN101933932B (en) | Application of 4-cyan-beta-D-glucoside in treating chronic neurogenic pain | |
| CN102512470B (en) | Pharmaceutical composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application | |
| CN101829128B (en) | Application of 4-formylphenyl-beta-D-glucoside compounds in treating chronic neuropathic pains | |
| CN101829126B (en) | Application of 3-carbethoxy phenyl-beta-D-glucoside in treating chronic neuropathic pains | |
| CN101837000B (en) | Application of 2-fluroin-beta-D-glycoside in treating neuropathic pain | |
| CN100574785C (en) | A kind of herbal mixture for the treatment of neuropathic pain | |
| CN105168201B (en) | Application of the Vitexin in pain medication after preparing iatrotechnics | |
| CN1322871C (en) | Preparation of compound pseudo-ginseng drop pellets for treating traumatologic disease | |
| CN1839974B (en) | Medicine composition for treating rheumatoid disease and method for preparing the same | |
| CN1720982A (en) | Sugar decreasing composition of fenugreek seed | |
| CN104784627A (en) | Traditional Chinese medicine externally used film agent used for treatment surgical open or closed injury and preparation method thereof | |
| CN111494446B (en) | Traditional Chinese medicine composition for treating biliary colic and application thereof | |
| CN101411700B (en) | Use of 5,7,4'-trihydroxy flavanone or derivative thereof for analgesia | |
| CN107281183B (en) | Analgesic composition | |
| CN102406924B (en) | Medicine composition for treating cerebrovascular and cardiovascular diseases as well as preparation method and application thereof | |
| CN107029047A (en) | A kind of medicament and its pharmaceutical formulation with analgesia wind-damp dispelling effect promoting blood circulation and removing blood stasis | |
| CN105998023B (en) | Application of demethylsinomenine in preparation of analgesic | |
| CN1194753C (en) | Medicine for treating head wind syndrome | |
| CN109045025A (en) | The new application of oxypeucedanin | |
| CN102824512A (en) | External plaster for treating joint pain | |
| CN111000925A (en) | External application Huojindan essential oil for treating soft tissue injury | |
| CN108686059A (en) | It is a kind of to be used to treat Chinese medicine composition of pain and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 Termination date: 20190316 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |